FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment

作者：Seiler Sarah^*; Reichart Birgit; Roth Daniel; Seibert Eric; Fliser Danilo; Heine Gunnar H

来源：Nephrology Dialysis Transplantation, 2010, 25(12): 3983-3989.

DOI：10.1093/ndt/gfq309

• cardiovascular mortality
• CKD
• FGF-23
• klotho
• phosphate

Background. High levels of the phosphaturic hormone fibroblast growth factor 23 (FGF-23) predict mortality in haemodialysis patients. The prognostic relevance of increased plasma FGF-23 levels in patients with less advanced chronic kidney disease (CKD) who are not on dialysis therapy is presently unknown.
Methods. We measured plasma c-terminal FGF-23 levels in 149 CKD patients not undergoing dialysis treatment. Patients were stratified by their baseline FGF-23 levels (> 104 vs <= 104 rU/mL) and followed for a period of 4.8 +/- 0.9 years. During the follow-up, the pre-specified combined clinical endpoint was the first occurrence of a cardiovascular event, e. g. myocardial infarction, coronary artery angioplasty/stenting/bypass surgery, stroke, carotid endarterectomy/stenting, non-traumatic lower extremity amputation, lower limb artery surgery/angioplasty/stenting or death.
Results. At baseline, elevated FGF-23 levels > 104 rU/mL were associated with more advanced CKD. Traditional cardiovascular risk factors and prevalent cardiovascular disease did not differ between CKD patients with high vs low FGF-23 levels. Fifty patients experienced a cardiovascular event during follow-up. Compared with CKD patients with FGF-23 <= 104 rU/mL, CKD patients with FGF-23 levels above the cut-off had worse event-free survival at univariate (log-rank test P=0.012) and multivariate analysis [hazard ratio 2.49 (95% CI 1.40-4.39); P=0.002].
Conclusions. Elevated FGF-23 plasma levels predict cardiovascular events in CKD patients not on dialysis therapy. This finding complements two recent cohort studies in which incident and prevalent haemodialysis patients with highest FGF-23 levels had worst survival. Lowering FGF-23 levels (e. g. by oral phosphate binder medication) could emerge as a promising new therapeutic option to reduce cardiovascular morbidity in CKD patients.

• 出版日期2010-12